- Pearl Academy explores the intersection of creativity and technology at its flagship event What’s Next
- Awareness programme Will be on PM VishwaKarma yojana on Tuesday
- Raveena soaks up some sunshine in Tadoba
- I will be in the contest Former TDP MLA Vetukuri Sivarama Raju
- Pawan asked me to go to Nidadavolu: Kandula Durgesh
- Filmmaker VN Aditya receives Doctorate from George Washington University of Peace, America
- Samsung to unveil Galaxy Ring at Mobile World Congress
- Kavitha urges CBI to withdraw notice in Delhi excise policy case
- PM Modi’s visit to Dwarkadhish temple, a message for Lord Krishna devouts?
- Nani collaborates with ‘OG’ director Sujeeth
Scientist a human guinea pig for malaria vaccine
In a world first a new malaria vaccine developed by Australian scientists has passed its first test in early human trials. Queensland scientists will ramp up tests of the vaccine, after its inventor tried it out by giving himself the disease.
Canberra: In a world first a new malaria vaccine developed by Australian scientists has passed its first test in early human trials. Queensland scientists will ramp up tests of the vaccine, after its inventor tried it out by giving himself the disease.
The vaccine, called PlasProtecT, developed by the researchers at Griffith University consists of inactivated human malaria parasites which have been prevented from growing and causing a malaria infection.
The vaccine works by stimulating a natural immune response which can protect a person for years against the mosquito-borne disease.
Lead researcher Michael Good, an immunologist with Griffith's Institute for Glycomics, was the first person to be immunised.
"I wouldn't ask people to do what I wouldn't be prepared to do, and we couldn't do this without the volunteers who give their time to us knowing they are helping further work towards a cure," Prof Good said.
It was later tested on another 11 people and proven to be safe and effective. "This is a world first," Gold Coast Health Director of Infectious Diseases Dr John Gerrard said.
"We are the first to put a vaccine like this into humans that has potential to protect against multiple strains and species of malaria," he said.
A much larger human clinical trial is now planned that will involve injecting participants with three doses of the vaccine and then infecting them with malaria to test the protection the vaccination provides.
Malaria is a mosquito-borne disease that kills up to half a million people each year, the vast majority of them children.
PlasProtecT represents a huge step forward in the fight against malaria, says Associate Professor Richard Culleton from the Malaria Unit at the Institute of Tropical Medicine at Nagasaki University in Japan.
Most excitingly, he says, the trials have shown that this human immune response also recognises other strains and even other species of the parasite.
"There are many different strains and species of malaria parasite in circulation, and finding a vaccine that can protect against them all has proven particularly troublesome so far," Prof Good said.